SCHEMBL1358287

SCHEMBL1358287

O=C(Cc1ccccc1)Oc1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.59
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
RECQL P46063 1/20 0.59
HSD17B10 Q99714 7/20 0.59
HPGD P15428 5/20 0.59
ALDH1A1 P00352 7/20 0.58
TSHR P16473 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
ESR1 P03372 1/20 0.58
ITGB3 P05106 1/20 0.58
ITGA2B P08514 1/20 0.58
HMGB1 P09429 1/20 0.58
GGT1 P19440 1/20 0.58
PTGS1 P23219 1/20 0.58
PTGS2 P35354 1/20 0.58
BLM P54132 1/20 0.58
NAPRT Q6XQN6 1/20 0.58
MAPT P10636 1/20 0.56
MAPK1 P28482 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6869020 0.88 MAPK1 (0.50) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL11622076 0.88 MAPK1 (0.52) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL10573912 0.87 MAPK1 (0.61) KMT2AHPGDALDH1A1TSHRTDP1
SCHEMBL5835239 0.86 KDM4E (0.56) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL8436639 0.85 KDM4E (0.63) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL6847069 0.85 MAPK1 (0.50) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL9092886 0.84 KDM4E (0.58) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL14036097 0.84 KDM4E (0.48) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL2906642 0.83 MAPK1 (0.49) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL27658575 0.83 SLC6A3 (0.62) KDM4EKMT2AMEN1RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822532-B1 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE COVESTRO DEUTSCHLAND AG (DE) 2018-09-19 EP claimed
EP-2196469-A1 Conjugates with anti-inflammatory activity GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2010-06-16 EP claimed
EP-1261347-B1 THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING PERIODONTITIS WITH ANTIINFLAMATORY COMPOUNDS UNIV RUTGERS (US) 2009-09-30 EP claimed
EP-1633771-B1 MACROLIDE-CONJUGATES WITH ANTI-INFLAMMATORY ACTIVITY GLAXOSMITHKLINE ZAGREB (HR) 2009-07-15 EP claimed
EP-2070940-A1 Compounds with anti-inflammatory activity GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2009-06-17 EP claimed
EP-1617816-B1 NANOPARTICULATE MELOXICAN FORMULATIONS ELAN PHARMA INT LTD (IE) 2009-05-13 EP claimed
EP-1551865-B1 HYBRID MOLECULES OF MACROLIDES WITH STEROIDAL/NON-STEROIDAL ANTI-INFLAMMATORY MOLECULES GLAXOSMITHKLINE ZAGREB (HR) 2009-04-22 EP claimed
US-20090048221-A1 Conjugates with Anti-Inflammatory Activity GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2009-02-19 US claimed
EP-1805202-A2 CONJUGATES WITH ANTI-INFLAMMATORY ACTIVITY PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2007-07-11 EP claimed
EP-1778292-A2 USE OF CELL-SPECIFIC CONJUGATES FOR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2007-05-02 EP claimed
WO-2006018698-A2 USE OF CELL-SPECIFIC CONJUGATES FOR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) 2006-02-23 WO claimed
US-20060035845-A1 Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract PLIVA-ISTRAZIVACKI INSTITUT D.O.O. 2006-02-16 US claimed
EP-1551865-A2 HYBRID MOLCULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES Pliva - Istrazivacki Institut d.o.o. (HR) 2005-07-13 EP claimed
US-20050080003-A1 Compounds with anti-inflammatory activity GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2005-04-14 US claimed
EP-1521763-A2 NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR THEIR USE Pliva - Istrazivacki Institut d.o.o. (HR) 2005-04-13 EP claimed
WO-2004094449-A1 MACROLIDE-CONJUGATES WITH ANTI-INFLAMMATORY ACTIVITY PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (US) 2004-11-04 WO claimed
US-20040097434-A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use PLIVA PHARMACEUTICAL INDUSTRY, INCORPORATED 2004-05-20 US claimed
US-20040077612-A1 Novel compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules PLIVA DD (HR) 2004-04-22 US claimed
WO-2004005313-A2 HYBRID MOLECULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) 2004-01-15 WO claimed
WO-2004005309-A2 NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR THEIR USE PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) 2004-01-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080003-A1 Compounds with anti-inflammatory activity NOD1, NOD2, TNF KDM4E 3272/4885KMT2A 4552/4885MEN1 3747/4885
US-20060035845-A1 Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract SI, MALT1, CD4 KDM4E 1989/4885KMT2A 3252/4885MEN1 4103/4885
US-20090048221-A1 Conjugates with Anti-Inflammatory Activity MPO, EPX, NOD1 KDM4E 2438/4885KMT2A 3277/4885MEN1 4318/4885
US-20040097434-A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use PTGS1, IL1B, LTB4R2 KDM4E 3705/4885KMT2A 4656/4885MEN1 4616/4885
US-20040077612-A1 Novel compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules MALT1, TNF, IL1B KDM4E 2444/4885KMT2A 4399/4885MEN1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.